L-tryptophan

L-Tryptophan

1. Identity, Chemical Nature, and Common Forms

L-Tryptophan (L-Trp) is a large neutral amino acid (LNAA) present in living organisms, precisely one of the 20 L-amino acids incorporated in proteins during the process of mRNA translation. L-Tryptophan is the unique protein amino acid bearing an indole ring: its biotransformation in living organisms contributes either to keeping this chemical group in cells and tissues or to breaking it, by generating in both cases a variety of bioactive molecules.

Its systematic chemical names include L-α-amino-3-indolepropionic acid, (S)-α-Amino-1H-indole-3-propanoic acid, L-β-3-indolylalanine, and 2-amino-3-indolylpropanoic acid. Its molecular formula is C₁₁H₁₂N₂O₂, and its CAS registry number is 73-22-3. The compound is the S-enantiomer (levorotatory form), biologically active in humans.

L-Tryptophan is an essential amino acid that must be part of the human diet. Among other functions, it enables the body to synthesize serotonin and melatonin. Tryptophan is not synthesized from simpler substances in humans and other animals and is sourced from dietary intake of tryptophan-containing proteins. Plants and microorganisms commonly synthesize tryptophan from shikimic acid or anthranilate.

L-tryptophan is an essential nutrient with an estimated adult intake of 600 to 1220 mg daily. The World Health Organization set the recommended Trp intake to 4 mg/kg/day, and, to date, no adverse effects of excess Trp in the diet have been reported.

As a supplement, L-tryptophan is commercially available primarily in the following forms:

• Oral capsules and tablets: Capsules commonly available at 500 mg.
• Powder: Bulk free-form crystalline L-tryptophan powder, used for flexible dosing.
• Licensed pharmaceutical preparations: The serotonin precursor L-tryptophan (TRP) is available as a nutritional supplement and is licensed as an antidepressant in a number of countries.

2. Natural Sources

Tryptophan, an essential amino acid, is commonly acquired from dietary sources such as turkey, eggs, cheese, tofu, seeds, and fish. Additional dietary sources include oats, bananas, dried prunes, milk, tuna fish, cheese, bread, poultry, peanuts, and chocolate. Tryptophan is an essential amino acid found primarily in proteinaceous food such as milk, tuna, turkey, oats, cheese, nuts, and seeds. Its availability is thus largely dependent on dietary intake.

Tryptophan is an exogenous amino acid that cannot be synthesized in the human body. It must be delivered through nutritional sources and, in the organism, it is found bound to albumin or in free form. Its concentration in the body is lower than that of other amino acids, and it might play a rate-limiting role in protein synthesis.

3. Traditional and Historical Use

Unlike many botanical dietary supplements with centuries of folk or indigenous use, L-tryptophan's history as a supplement is relatively modern and tied to the development of biochemistry. Tryptophan as a distinct chemical entity was first isolated in the early twentieth century, and interest in its supplemental use emerged primarily in the second half of the twentieth century, following the elucidation of its role as the precursor to serotonin.

Tryptophan is important both for protein synthesis and as a precursor of niacin, serotonin and other metabolites. Tryptophan is an unusual amino acid because of the complexity of its metabolism, the variety and importance of its metabolites, the number and diversity of the diseases it is involved in, and because of its use in purified form as a pharmacological agent.

L-tryptophan has long been approved by the Federal FDA as a dietary supplement, but the compound has not yet been the subject of an approved New Drug Application (NDA), despite its established and expanding pharmacology in the literature. L-tryptophan is an exogenous amino acid that is converted into serotonin, and has been studied extensively through the 1960s to 1980s in the treatment of insomnia and depression.

A key event in its regulatory history was the 1989 outbreak associated with contaminated batches: FDA took action to limit the availability of dietary supplements containing L-Tryptophan because of the association between dietary supplements containing L-Tryptophan and the 1989 epidemic outbreak of eosinophilia-myalgia syndrome (EMS) in the United States. In all, more than 1500 cases of EMS, including at least 37 deaths, were reported to the national Centers for Disease Control and Prevention (CDC), although the true incidence of the disorder is thought to be much higher. This outbreak was first considered to be a direct effect of L-tryptophan but was later determined to be due to impurities in batches produced by a particular manufacturer. The association led the FDA to ban the sale of L-tryptophan in 1991. Subsequently, however, the development of EMS in association with L-tryptophan was related to contaminants in the supply produced by a particular manufacturer. The FDA lifted the ban on L-tryptophan in 2001.

4. Key Constituents and Mechanisms of Action

An essential component of the human diet, L-tryptophan is critical in a number of metabolic functions and has been widely used in numerous research and clinical trials. This review provides a brief overview of the role of L-tryptophan in protein synthesis and a number of other metabolic functions. With emphasis on L-tryptophan's role in synthesis of brain serotonin, details are provided on the research uses of L-tryptophan, particularly L-tryptophan depletion, and on clinical trials that have been conducted using L-tryptophan supplementation. The ability to change the rates of serotonin synthesis in the brain by manipulating concentrations of serum tryptophan is the foundation of much research. As the sole precursor of serotonin, experimental research has shown that L-tryptophan's role in brain serotonin synthesis is an important factor involved in mood, behavior, and cognition.

4.1 The Three Major Catabolic Pathways

Physiologically, approximately 5% of dietary tryptophan is catabolized through the pathway forming serotonin and melatonin in the brain and enterochromaffin cells of the gut, approximately 85% through the pathway resulting in the formation of nicotinamide nucleotides and kynurenine and its derivatives in the liver and immune cells, and approximately 10% in gut microbiota to indole derivatives.

Tryptophan metabolism involves three primary pathways: the kynurenine (Kyn) pathway, the 5-hydroxytryptamine (serotonin, 5-HT) pathway, and the indole pathway. Under normal physiological conditions, tryptophan metabolism plays crucial roles in regulating inflammation, immunity, and neuronal function. Key rate-limiting enzymes such as indoleamine-2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO), and kynurenine monooxygenase (KMO) drive these metabolic processes.

4.2 The Serotonin Pathway

In addition to protein turnover, in humans the pathways of Trp indole derivatives cover the synthesis of the neurotransmitter/hormone serotonin (5-HT), the pineal gland melatonin (MLT), and the trace amine tryptamine. L-tryptophan is an essential amino acid found in plant and animal proteins, absorbed from dietary protein sources and converted to 5-hydroxytryptophan (5-HTP) and then to serotonin (5-hydroxytryptamine).

Once in the CSF, tryptophan is converted into serotonin in the raphe nuclei by the normal enzymatic pathway. The resultant serotonin is further metabolised into the hormone melatonin — an important mediator of the circadian rhythm — by the pineal gland.

4.3 The Kynurenine Pathway

The breakdown of the Trp indole ring defines the "kynurenine shunt" which produces cell-response adapters as L-kynurenine, kynurenic and quinolinic acids, or the coenzyme nicotinamide adenine dinucleotide (NAD⁺). Two enzymes, namely indoleamine 2,3-dioxygenase (IDO) in the immune system and the brain, and tryptophan 2,3-dioxygenase (TDO) in the liver, are responsible for the synthesis of kynurenine from tryptophan. The kynurenine pathway of tryptophan catabolism is altered in several diseases, including psychiatric disorders such as schizophrenia, major depressive disorder, and bipolar disorder.

The first stage of this pathway is catalyzed by the hepatic enzyme tryptophan 2,3-dioxygenase (TDO) and the extrahepatic enzyme indoleamine 2,3-dioxygenase (IDO), enzymes that are induced by glucocorticoids and pro-inflammatory cytokines, respectively. Thus, chronic stress and infections can shunt available tryptophan toward the kynurenic pathway and thereby lower 5-HT synthesis.

The balance between neuroprotective metabolites, including kynurenic acid, and neurotoxic compounds, such as quinolinic acid, is crucial for maintaining neural homeostasis and influences the risk and progression of neuropsychiatric and neurodegenerative disorders.

4.4 Niacin and NAD+ Synthesis

Niacin, also known as vitamin B3, is synthesized from tryptophan via kynurenine and quinolinic acids. The coenzymes nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP) are also products of tryptophan catabolism. NAD and NADP are coenzymes essential for redox reactions in all living cells. Deficiency of tryptophan, which is an essential amino acid, may lead to pellagra.

4.5 The Gut Microbial Indole Pathway

Tryptophan is an essential amino acid that is metabolized in the gastrointestinal tract by both host and gut microbiota, resulting in a variety of metabolites, which can affect host metabolism and homeostasis. Tryptophan is readily utilized by several gut microbial species, which catabolize it to metabolites including indole, indolelactic acid (ILA), indoleacrylic acid (IAcrA), indolepropionic acid (IPA), indoleacetic acid (IAA), indolealdehyde (IAld), and tryptamine. These metabolites regulate host biological processes such as maintenance of epithelial barrier integrity, immune response, protection against pathogens, inflammation, and metabolic disorders.

4.6 Additional Metabolites

In addition to tryptophan's three major activities of protein, kynurenine, and serotonin synthesis, tryptamine is another biologically active compound that is derived from tryptophan. After protein synthesis, the second most prevalent metabolic pathway of tryptophan is for the synthesis of kynurenine, which accounts for approximately 90% of tryptophan catabolism. The immediate decarboxylation of tryptophan results in the synthesis of trace amounts of tryptamine, which is an important neuromodulator of serotonin. Melatonin is a hormone produced in the tryptophan/serotonin pathway, which regulates diurnal rhythms and influences the reproductive and immune systems, as well as digestive processes and gastrointestinal motility.

4.7 Blood-Brain Barrier Transport

L-Tryptophan is a large neutral amino acid (LNAA). Its entry into the central nervous system across the blood-brain barrier is mediated by a shared carrier transport system, competing with other large neutral amino acids such as phenylalanine, tyrosine, and branched-chain amino acids. The ratio of tryptophan to other LNAAs in the plasma is therefore an important determinant of brain serotonin synthesis, which is why carbohydrate-rich meals (which reduce competing amino acid levels) can increase tryptophan's brain uptake. L-tryptophan is metabolized by a non-CYP450 liver pathway, with a half-life of 3–4 hours.

5. Scientific Evidence by Area of Use

5.1 Sleep and Insomnia

Sleep is the most extensively researched application of supplemental L-tryptophan. The weight of evidence indicates that L-tryptophan in doses of 1 g or more produces an increase in rated subjective sleepiness and a decrease in sleep latency (time to sleep).

A double-blind controlled study examined: The effects of 3 g L-tryptophan on sleep, performance, arousal threshold, and brain electrical activity during sleep were assessed in 20 male, chronic sleep-onset insomniacs (mean age 20.3 ± 2.4 years). Following a sleep laboratory screening night, all subjects received placebo for 3 consecutive nights (single-blind), ten subjects received L-tryptophan, and ten received placebo for 6 nights (double-blind). There was no effect of L-tryptophan on sleep latency during the first 3 nights of administration. On nights 4–6 of administration, sleep latency was significantly reduced. Unlike benzodiazepine hypnotics, L-tryptophan did not alter sleep stages, impair performance, elevate arousal threshold, or alter brain electrical activity during sleep.

A double-blind cross-over study in chronic insomnia: Thirty-nine subjects with chronic insomnia were treated with L-tryptophan (L-TRP) in a double-blind, cross-over study. Instead of a placebo, a very low dose of 0.04 g L-TRP was used.

A randomized, double-blind, placebo-controlled trial in a drug dependence context: Forty-five participants completed the 2-week study, 24 in the tryptophan group and 21 in the placebo group. There were no statistically significant differences in baseline characteristics between groups. The reduction in the Athens Insomnia Scale score in the tryptophan group was significantly greater than that in the placebo group (P = 0.017). However, no significant differences were found in Symptom Check-List-90 scores between groups. The frequency of adverse events was similar and no serious adverse events were reported during the study. Tryptophan was unlikely to be effective for mental symptoms, but could alleviate sleep disorders in the short term among detoxified individuals with new-type drug dependence.

A systematic review and meta-analysis found: A systematic review and meta-analysis assessed the effects of tryptophan supplementation on sleep quality. The analysis revealed that tryptophan, particularly at doses of 1 gram or more, significantly reduced wakefulness after sleep onset. Specifically, a dose of 1 gram or more shortened wakefulness by approximately 81 minutes per gram. However, other sleep components were not significantly affected by tryptophan supplementation.

Evidence strength assessment: For reducing sleep latency and subjective sleepiness at doses of 1 g or more, evidence is moderately supportive, drawn from multiple controlled trials conducted mainly from the 1970s through the 1990s. The effect on overall sleep architecture is less firmly established, and much of the foundational research involved small sample sizes. Many RCTs lacked methodological rigor, and were commonly excluded due to small sample size or an inadequate control condition.

5.2 Mood, Depression, and Emotional Functioning

As the sole precursor of serotonin, experimental research has shown that L-tryptophan's role in brain serotonin synthesis is an important factor involved in mood, behavior, and cognition. Furthermore, clinical trials have provided some initial evidence of L-tryptophan's efficacy for treatment of psychiatric disorders, particularly when used in combination with other therapeutic agents.

In depression, patients at risk tend to respond with a negative mood to 'acute tryptophan depletion' (ATD), while healthy volunteers and current patients do not. The serotonergic system thus provides indications for vulnerability for depression. This depletion research provides indirect evidence that maintaining adequate tryptophan availability is important for mood stability.

Decreased availability of 5-HT in the brain is a key feature in the pathogenesis of depression. In the case of IDO1 pathway overactivation, such as that occurring in chronic inflammatory diseases or in patients treated with interferon for hepatitis C, tryptophan is massively diverted to the production of kynurenine, causing a deficiency in brain tryptophan and in 5-HT production, subsequently leading to depression.

Evidence for use in depression is limited but suggestive. L-tryptophan in depression is extremely limited. For depression, doses as low as 300 mg/day in combination with antidepressants have been used.

Evidence strength assessment: Direct evidence from clinical trials using L-tryptophan supplementation alone for major depressive disorder is limited and largely preliminary. The strongest mechanistic link comes from acute tryptophan depletion studies, which show mood lowering in vulnerable individuals, but supplementation trials in frank depression have been small and methodologically inconsistent. The licensed use as an antidepressant in certain countries (e.g., the UK, where it was licensed as Optimax) reflects clinical consensus in specific contexts rather than robust large-scale randomized controlled trial evidence.

5.3 Premenstrual Dysphoric Disorder (PMDD)

Antidepressant drugs, including specific serotonin reuptake inhibitors, have been shown to be beneficial in the treatment of premenstrual dysphoric disorders. The present study tested the efficacy of L-tryptophan, which acts specifically on serotonergic neurons, in this disorder.

The most notable clinical trial in this area: In a randomized controlled clinical trial, 37 patients with premenstrual dysphoric disorder were treated with L-tryptophan 6 g per day, and 34 were given placebo. The treatments were administered under double-blind conditions for 17 days, from the time of ovulation to the third day of menstruation, during three consecutive menstrual cycles. The Visual Analogue Scales (VAS) revealed a significant (p = .004) therapeutic effect of L-tryptophan relative to placebo for the cluster of mood symptoms comprising the items of dysphoria, mood swings, tension, and irritability. These results suggest that increasing serotonin synthesis during the late luteal phase of the menstrual cycle has a beneficial effect in patients with premenstrual dysphoric disorder.

A 1999 placebo-controlled trial of 6 g daily L-tryptophan in 37 women with premenstrual dysphoric disorder reported modest reductions in dysphoria and irritability during the luteal phase, attributed to enhanced serotonin synthesis. Effect sizes were small, and subsequent research has not yielded large confirmatory trials.

Evidence strength assessment: Best efficacy for PMDD has been reported in the literature, but this rests on a single primary controlled trial. The finding is biologically plausible and statistically significant but requires replication in larger studies before firm conclusions can be drawn.

5.4 Anxiety

Evidence regarding L-tryptophan supplementation for anxiety in humans is less direct. Research has predominantly used the acute tryptophan depletion (ATD) paradigm to study the serotonin-anxiety relationship. A systematic review of 21 studies on ATD and anxiety concluded: In total, 21 studies were included. Studies were conducted in healthy volunteers (n = 13), and patients with a remitted (n = 6) or current (panic, social or generalised) anxiety disorder (n = 4). Studies were mostly of poor quality and heterogeneous regarding population, challenge test used and outcome measures. ATD did not consistently affect anxiety in any of the groups. Moreover, a challenge test after ATD did not consistently provoke anxiety in healthy volunteers or remitted patients.

Evidence strength assessment: Evidence that L-tryptophan supplementation reduces anxiety symptoms in clinical populations is weak and inconsistent. The depletion literature suggests tryptophan availability may matter more in panic disorder under challenge conditions, but direct supplementation trials targeting anxiety disorders as a primary outcome are sparse.

5.5 Smoking Cessation

Evidence for best efficacy in smoking cessation has been noted in summaries of clinical research. Human research indicates that L-tryptophan might help reduce cigarette cravings in people who are quitting smoking. The daily dose used was 50 mg/kg of L-tryptophan (approximately 4 g per day for an 80 kg person), taken together with a high-carbohydrate diet and conventional smoking cessation techniques. A 1991 study found that this combination lowered self-reported anxiety and craving intensity versus controls during smoking cessation attempts. Outcomes were subjective and limited in scope.

Evidence strength assessment: Preliminary; based on a small number of trials, most from the early 1990s. The use of a high-carbohydrate diet as an adjunct complicates isolating tryptophan's specific contribution. Larger, more rigorous contemporary trials are lacking.

5.6 Gut Health, the Microbiome, and Intestinal Barrier Function

Among the metabolites that play an important role within intestinal health, L-Tryptophan is one of the nine essential amino acids supplied by diet, whose metabolism appears as a key modulator of gut microbiota, with major impacts on physiological and pathological pathways. Emerging evidence showed that tryptophan catabolism through IDO1 expressed by the host affects tryptophan metabolism by gut microbiota to generate indole metabolites, thereby altering gut function and health in mice and humans.

Tryptophan appears to be an important amino acid in IBD patients since they have lower levels of serum and fecal tryptophan compared to healthy subjects. Dysregulation of tryptophan metabolites plays a central role in the pathogenesis of many neurologic and psychiatric disorders. Gut microbes influence tryptophan metabolism directly and indirectly, with corresponding changes in behavior and cognition. The gut microbiome has thus garnered much attention as a therapeutic target for both neurologic and psychiatric disorders where tryptophan and its metabolites play a prominent role.

Evidence strength assessment: The role of tryptophan in gut barrier integrity and microbiome modulation is an active and rapidly growing research area, but much of the mechanistic evidence remains pre-clinical (animal and in vitro). Human interventional data specifically using L-tryptophan supplementation for gut disorders are still preliminary.

5.7 Neuroinflammation and Psychiatric Vulnerability

Inflammation-induced activation of indoleamine 2,3-dioxygenase (IDO) shifts tryptophan metabolism toward the kynurenine pathway, reducing serotonin synthesis and increasing neurotoxic metabolites such as quinolinic acid. Approximately 90% of dietary tryptophan is metabolized through the kynurenine pathway, generating neuroactive compounds such as kynurenic acid and quinolinic acid, while a smaller fraction is converted to serotonin. The balance between neuroprotective metabolites, including kynurenic acid, and neurotoxic compounds, such as quinolinic acid, is crucial for maintaining neural homeostasis and influences the risk and progression of neuropsychiatric and neurodegenerative disorders.

The kynurenine pathway of tryptophan catabolism is altered in several diseases, including psychiatric disorders such as schizophrenia, major depressive disorder, and bipolar disorder. This body of research is largely mechanistic and observational; clinical supplementation trials for these specific psychiatric indications remain limited.

6. Body Systems Associated with L-Tryptophan

• Central Nervous System: Precursor to serotonin and melatonin, implicated in mood, cognition, sleep, appetite regulation, and circadian rhythm.
• Endocrine System: Melatonin is a hormone produced in the tryptophan/serotonin pathway, which regulates diurnal rhythms and influences the reproductive and immune systems.
• Gastrointestinal System: Tryptophan metabolism appears as a key modulator of gut microbiota, with major impacts on physiological and pathological pathways.
• Immune System: Under normal physiological conditions, tryptophan metabolism plays crucial roles in regulating inflammation and immunity.
• Metabolic / Nutritional System: Essential substrate for protein synthesis; precursor to niacin (vitamin B3) and the coenzymes NAD⁺ and NADP⁺.
• Reproductive System (female): Implicated in PMDD through serotonin-dependent modulation of late-luteal-phase mood symptoms.

7. Dosage Forms and Doses Reported in Studies

The following dosage information is drawn directly from published clinical and research sources:

• Sleep / insomnia: L-tryptophan in doses of 1 g or more produces an increase in rated subjective sleepiness and a decrease in sleep latency. A specific study used 3 g L-tryptophan in chronic sleep-onset insomniacs.
• PMDD: 37 patients with premenstrual dysphoric disorder were treated with L-tryptophan 6 g per day in a double-blind, randomized controlled trial.
• Smoking cessation: The daily dose used was 50 mg/kg of L-tryptophan (approximately 4 g per day for an 80 kg person), taken together with a high-carbohydrate diet.
• Depression (combination): For depression, doses as low as 300 mg/day in combination with antidepressants have been used.
• General supplemental range: For other uses, dose is typically 500–1000 mg BID or 500 mg TID.
• EMS outbreak context: The duration of L-tryptophan use spanned from days to years with doses ranging from 26 mg to 15,000 mg per day; median, 1500 mg per day.
• Estimated normal dietary intake: An estimated adult intake of 600 to 1220 mg daily from food.

8. Safety Considerations and Drug Interactions

8.1 Eosinophilia-Myalgia Syndrome (EMS)

Safety concerns have been raised since a disease known as eosinophilia-myalgia syndrome (EMS) was reported to be related to L-tryptophan supplements. EMS is a rare condition characterized by inflammation in various organ systems including the muscles, skin, and lungs. Symptoms of EMS include eosinophilia, fatigue, myalgia, neuropathy, rash, and inflammation.

Through several studies, it has been speculated that six components generated during the process of L-tryptophan synthesis are related to the induction of EMS. This outbreak was first considered to be a direct effect of L-tryptophan but was later determined to be due to impurities in batches produced by a particular manufacturer. In epidemiological studies conducted in the 1990s, 97–100% of EMS cases meeting the Centers for Disease Control (CDC) criteria were deemed to have been caused by contamination that occurred during changes in manufacturing processes.

Over 1,500 reports of eosinophilia-myalgia syndrome (EMS) and 37 deaths were reported in the US, leading to it being pulled from the market in 1990; nearly all cases were tied to contaminated batches out of Japan. There have been no reported recurrences of these reactions since that outbreak. However, occasional case reports of EMS in association with L-tryptophan have been made, and the NIH continues to urge that caution be applied because the risk has not been fully characterized.

8.2 Serotonin Syndrome Risk

Combining L-tryptophan with serotonergic antidepressants may increase risk of serotonin syndrome. Avoid use with MAOIs. Citalopram and L-tryptophan both increase serotonin levels. Avoid or use an alternate drug, as the combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.

Interactions are documented with multiple serotonergic agents: Dextromethorphan and L-tryptophan both increase serotonin levels, requiring monitoring and possible therapy modification. L-tryptophan and lithium both increase serotonin levels, warranting caution and monitoring.

8.3 Sedative Drug Interactions

Medications that cause sleepiness are called sedatives. Taking L-tryptophan along with sedative medications might cause too much sleepiness. Some sedative medications include clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), and zolpidem (Ambien).

8.4 Common Adverse Effects

According to the NIH, L-tryptophan supplements can have side effects, with some of the most common being heartburn, stomach pain, and nausea.

8.5 Special Populations

Pregnancy/breastfeeding: Not enough data to recommend.

8.6 Regulatory Status

In the United States (FDA), L-tryptophan is a dietary supplement, re-authorized in 2005 after a 1989–2005 ban. Although FDA continues to enunciate its concern about the safety of dietary supplements containing L-Tryptophan and related compounds such as L-5-hydroxytryptophan, this does not mean that FDA prohibits the marketing of dietary supplements that contain L-Tryptophan.

References

• Palego L, Betti L, Rossi A, Giannaccini G. Tryptophan Biochemistry: Structural, Nutritional, Metabolic, and Medical Aspects in Humans. Journal of Amino Acids. 2016;2016:8952520. PMC4737446.
• Richard DM, Dawes MA, Mathias CW, et al. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int J Tryptophan Res. 2009;2:45–60. PMC2908021.
• Sainio EL et al. L-Tryptophan: Biochemical, nutritional and pharmacological aspects. Amino Acids. 1996;10(1):21–47. PubMed 24178430.
• Sadok I, Sidor K. Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease. Nutrients. 2026;18(3):507.
• L-Tryptophan: CID 6305. PubChem, National Institutes of Health (NIH).
• Hartmann E. Effects of L-tryptophan on sleepiness and on sleep. Journal of Psychiatric Research. 1982.
• Schneider-Helmert D, Spinweber CL. L-tryptophan administered to chronic sleep-onset insomniacs: late-appearing reduction of sleep latency. Psychopharmacology. 1986;89(2):195–197. PMID 3097693.
• Demisch K, Bauer J, Georgi K, Demisch L. Treatment of severe chronic insomnia with L-tryptophan. Pharmacopsychiatry. 1987;20(6):242–4. PMID 3432357.
• Wu X et al. Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial. Medicine. 2016. PMC4956795.
• Steinberg S, Annable L, Young SN, Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. J Psychiatry Neurosci. 1999;24(1):15–22. PMID 10023508.
• Schopman SME et al. Effects of tryptophan depletion on anxiety, a systematic review. Translational Psychiatry. 2021;11:114. PMC7878770.
• Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host & Microbe. 2018;23(6):716–724.
• Roager HM, Licht TR. Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases. Frontiers in Immunology. 2019;10:2113. PMC6746884.
• Zhao J et al. Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer. Molecular Cancer. 2024.
• Impurities in L-Tryptophan associated with eosinophilia myalgia syndrome. Food and Chemical Toxicology. 2023.
• FDA Information Paper on L-Tryptophan and 5-hydroxy-L-tryptophan. U.S. Food and Drug Administration.
• Cervenka I, Agudelo LZ, Ruas JL. Tryptophan Metabolic Pathways and Brain Serotonergic Activity: A Comparative Review. Frontiers in Neuroscience. 2017. PMC6463810.
• Lavelle A et al. Gut Microbiota-Derived Tryptophan Metabolites Maintain Gut and Systemic Homeostasis. Cells. 2022. PMC9330295.
• L-Tryptophan Fact Sheet. The Carlat Report / Medication Fact Books.
• Tryptophan (L-tryptophan) dosing, indications, interactions, adverse effects. Medscape Reference.